RxDoctor Payments Data

Richard Fruehling, MD

Family Medicine · Grand Island, NENPI 1851347611

Payments from drug & device makers

$895in general payments, 2019–2025

Across 47 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$167
  • AbbVie$103
  • Abbott$97
  • Lilly USA, LLC$63
  • E.r. Squibb & Sons, L.L.C.$58
  • AstraZeneca$42
  • plus $365 from 14 others

What the payments were for

  • Food & beverage$895100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$895 in reported general payments places this provider in the 55th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$251,288
Medicare patients
402
Services billed
7,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$90,873
OzempicSemaglutide81$84,890
FarxigaDapagliflozin Propanediol62$59,538
TrulicityDulaglutide44$43,850
ArexvyRsvpref3 Antigen/As01e/Pf126$38,903
MyrbetriqMirabegron50$22,695
ShingrixVaricella-Zoster Ge/As01b/Pf103$22,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,827
Potassium Chloride459$18,599
VraylarCariprazine Hcl12$17,454
XareltoRivaroxaban28$14,084
Tresiba Flextouch U-100Insulin Degludec20$12,456
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$11,862
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$9,316
Fluticasone-SalmeterolFluticasone Propion/Salmeterol48$9,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta$30$95,613284 claims
Novo NordiskOzempic$167$84,89081 claims
AstraZenecaFarxiga$42$59,53862 claims
Lilly USA, LLCTrulicity$63$43,85044 claims
AbbVieVraylar$103$17,45412 claims
Johnson & JohnsonXarelto$23$14,08428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →